Advertisement
Australia markets closed
  • ALL ORDS

    8,323.50
    +30.40 (+0.37%)
     
  • ASX 200

    8,099.90
    +24.20 (+0.30%)
     
  • AUD/USD

    0.6706
    -0.0018 (-0.26%)
     
  • OIL

    69.24
    +0.27 (+0.39%)
     
  • GOLD

    2,606.20
    +25.60 (+0.99%)
     
  • Bitcoin AUD

    89,527.34
    -918.42 (-1.02%)
     
  • XRP AUD

    0.89
    +0.03 (+3.81%)
     
  • AUD/EUR

    0.6051
    -0.0016 (-0.26%)
     
  • AUD/NZD

    1.0884
    +0.0014 (+0.13%)
     
  • NZX 50

    12,832.55
    +12.27 (+0.10%)
     
  • NASDAQ

    19,514.58
    +91.52 (+0.47%)
     
  • FTSE

    8,273.09
    +32.12 (+0.39%)
     
  • Dow Jones

    41,393.78
    +297.01 (+0.72%)
     
  • DAX

    18,699.40
    +181.01 (+0.98%)
     
  • Hang Seng

    17,369.09
    +128.70 (+0.75%)
     
  • NIKKEI 225

    36,581.76
    -251.51 (-0.68%)
     

Penumbra Second Quarter 2024 Earnings: EPS Misses Expectations

Penumbra (NYSE:PEN) Second Quarter 2024 Results

Key Financial Results

  • Revenue: US$299.4m (up 14% from 2Q 2023).

  • Net loss: US$60.2m (down by 418% from US$19.0m profit in 2Q 2023).

  • US$1.55 loss per share (down from US$0.49 profit in 2Q 2023).

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

Penumbra EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates.

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are down 12% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 2 warning signs for Penumbra you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com